Head to head
Qiagen NV vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: QGEN · TMO
QGEN
Qiagen NV
44.79-1.88%
1-year price shape — -3% over the period
Quant Rating D · 34/100
vs
TMO
Thermo Fisher Scientific
662.06+0.83%
1-year price shape — +23% over the period
Quant Rating C · 64/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific has the highest Quant Rating (64); Thermo Fisher Scientific has done best over the past year (+23%); Thermo Fisher Scientific earns the most per share.
| QGEN | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 44.79 | 662.06 |
| Change today | -1.88% | +0.83% |
| 1-year return | -3.4% | +23.1% |
| Market cap | $9.25B | $244.79B |
| 52-week range | 32.24 – 57.30 | 434.50 – 694.33 |
| Valuation | ||
| P/E (TTM) | 22.77 | 35.63 |
| P/E percentile, own 5-yr range | 28th | 86th |
| P/B | 2.75 | 4.65 |
| Dividend yield | 0.78% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | 1.94 | 17.74 |
| Net profit (TTM) | $400.60M | $6.56B |
| Revenue (TTM) | $2.10B | $46.34B |
| Revenue growth (YoY) | +0.3% | +10.5% |
| Gross margin | 62.2% | 40.8% |
| Operating margin | 24.6% | 18.3% |
| Net margin | 19.5% | 15.0% |
| Free cash flow (TTM) | $440.60M | $7.32B |
| Ownership & sentiment | ||
| Institutional ownership | 76.0% | 93.1% |
| Insider activity (12mo) | 0 buy / 5 sell | 22 buy / 28 sell |
| Short interest (% of float) | 3.7% | 1.4% |
| Analyst consensus | 50% buy / 50% hold (8) | 88% buy / 12% hold (17) |
| Analyst price target | $46 (+4%) | $653 (-1%) |
| StockVane view | ||
| StockVane Quant Rating | D (34) | C (64) |
| Company | ||
| Employees | 5,654 | 125,000 |
| Founded | 1996 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.